Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
12:531–534 © 1996 Lippincott–Raven Publishers, Philadelphia

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology Volume 12, 1996

Author Index

Abrams DI, 56, 386
Achenbach C, 379
Adams J, 379
Aebischer LM, 63
Agins BD, 508
Ahmed OI, 528
Åkerblom L, 213
Alcabes P, 33
Allegre T, 95
Almirante B, 93
Aluigi G, 164
Antia R, 233
Antunes F, 249
Araki K, 182
Arima N, 182
Arseneau R, 153
Assunçao RM, 371

Bailey TC, 147
Bain RM, 400
Baker H, 75
Banea M, 317
Bare P, 428
Barker H, 519
Bartolomé R, 93
Bavry AA, 528
Beauchamp D, 451
Bedjabaga I, 187
Beecham HJ III, 358
Bennett CL, 379
Benson CA, 147
Bergeron L, 321
Bergeron MG, 451
Besmyter J, 208
Beuselinck K, 208
Beyrer C, 495
Biberfeld G, 317, 421
Birx DL, 329
Biswas DK, 120
Blaschke T, 363
Blattner WA, 519
Blibolo D, 290
Bloom PA, 209
Bogden JD, 75
Bolmstedt A, 213
Booth RE, 202
Borliden K, 221
Boswell RN, 329
Böttiger B, 317
Boufassa F, 174
Brandi G, 164
Bredberg-Rådén U, 421
Brining S, 1
Brinkmann U, 500
Broliden P-A, 221
Brookmeyer R, 495
Brosgart CL, 56
Brown AJL, 6
Bryant JL, 309
Bueno RC, 84
Burack JH, 386
Burattini MN, 84
Burger H, 352
Burke DS, 329
Burwen DR, 293
Busch MP, 193, 427

Calarota SA, 527
Caldarelli R, 139
Campbell TB, 363
Campelli A, 158
Carlin JB, 371
Carlo DJ, 358
Carré N, 174
Cartoux M, 290
Carvalho HB de, 84
Carvalho MB, 526
Casabianca A, 164
Caselli D, 158
Cegielski JP, 303
Celentano DD, 495
Charlebois E, 56
Cheeseman SH, 147
Chiarantini L, 164
Chiodo F, 319
Chirgwin KD, 489
Chiyoda S, 182
Chmiel JS, 309
Chutkowski C, 99
Cinque P, 139
Circella A, 112
Cleator GM, 394
Cleland A, 6
Clerici M, 158
Clotet B, 249
Cohen MR, 386
Cohn SE, 379
Coleman R, 56
Collier A, 363
Corbin DOC, 519
Cord-Cruz EA, 514
Coronado OV, 319
Costa F, 63
Costanzi G, 139
Cotropia J, 221
Cotton D, 38
Coulibaly D, 290
Currier RJ, 309

Dabis F, 290
Dally LG, 462
Danner SA, 276
Davison D, 519
Dazza M-C, 187
De Rienzo B, 462
Dearden C, 519
DeHovitz JA, 379
Del Pino N, 525
Delaporte E, 187
Denner J, 442
Derito C, 525
Derse D, 1
Désormeaux A, 451
Dianzani F, 462
Dickinson GM, 379
Dieguez-Lucena JL, 107
Dodd CL, 470
Dolin R, 38
Doroana M, 249
Dubon JM, 529
Dunagan WC, 94
Dusserre N, 451
Dwyer J, 523

Endert E, 482
Engelbrecht S, 298
Ernst J, 96, 431
Essex M, 19
Evans AS, 519
Evans DB, 371

Factor SH, 96, 431
Fang G, 352
Fanning TR, 259

Farthing C, 147
Feinberg J, 38, 147
Feldman J, 489
Felton S, 519
Fernández-Arcás N, 107
Ferrante P, 139
Ferreira MMC, 526
Ferreira OC Jr, 526
Fichtenbaum CJ, 94
Fiebig E, 427
Finkelstein DM, 38
Flandre P, 174
Fleming PL, 293
Floridia M, 462
Fragola V, 462
Fraternael A, 164
Friedland G, 33
Frissen PHJ, 482

Gabiano C, 158
Gable CB, 413
Galli L, 158
Galli M, 268
García-Saiz A, 529
García-Villanova J, 107
Gardiner S, 371
Garofalo T, 112
Gatell JM, 249
Gattinara GC, 158
Gerard L, 174
Gervasoni C, 268
Gil-Aguado A, 249
Gill J, 153
Gilman SC, 379
Girardi E, 63
Glowaczower E, 187
Goldstein RS, 406
Gomez MP, 400
Goubau P, 208
Gourde P, 451
Grace, CJ, 358
Gray H, 400
Greene WC, 343
Greenspan D, 470
Griggi T, 112
Gross M, 406
Guzzanti E, 63

Hack CE, 276
Hahn JA, 386
Hamerschlak N, 526
Han Y, 508
Hansen J-ES, 213
Harrison C, 514
Harvie P, 451
Hauck WW, 259
Haustein D, 442
Hayami M, 428
Hemming A, 213
Heneine W, 193
Herman SA, 427
Hermansen S, 193
Hersh EM, 358
Hilton JF, 470
Hoover DR, 309
Horner RD, 379
Hosokawa T, 182
Hoxie JA, 221
Hu S-L, 213
Hurley SF, 371
Hurwitz S, 147

Ikeda S, 182
Ippolito G, 63
Irwin KL, 96, 431

Jansen J, 482
Jarlais DCD, 514
Jaureguiberry JP de, 95
Jenkins S, 99
Jimenez A, 282
Johnson W, 282
Jones JL, 293
Jou A, 249
Jovanovic B, 282

Kahn J, 38, 363
Kaldor JM, 371
Kaplan JE, 193
Kaplanski G, 95
Karlsson K, 421
Kasparova L, 249
Kaufman G, 508
Kawano F, 182
Kawo G, 421
Kazimoto T, 421
Kemp FW, 75
Kerouedan D, 187
Kessler HA, 147
Khabbaz RF, 193
Khamboonruang C, 495
Kikuchi H, 182
Kim JH, 329, 343
Kinoshita K-I, 182
Kleinman S, 193
Kliks S, 221
Koester S, 202
Kohno H, 182
Kondo E, 321
Korvick JA, 147
Krasinski K, 514
Krushner N, 99
Kunawararak P, 495
Kuritzkes DR, 147, 363
Kurth R, 442

LaCasse RA, 26
Lafeuillade A, 95
Lal RB, 96, 193, 431
Lallinger GJ, 303
Lampinen T, 282
Lam-Po-Tang R, 523
Landesman S, 489
Landry ML, 33
Lange JMA, 482
Larouzé B, 187
Lee T-H, 19, 427
LeFaile M, 99
Letvin N, 99
Levin BR, 233
Levine AM, 358
Li J, 99
Libonatti OV, 525, 527
Lonzález-Lahoz J, 249
Lopes GT, 84
Losina E, 406
Louria DB, 75
Louwagie J, 187
Lovicu GF, 268
Lu Y, 99
Lucas GS, 394
Lucey DR, 19
Ludlam CA, 6
Lupo A, 268
Lyamuya E, 421

MacPhail LA, 470
Magnani M, 164
Major C, 400
Mandelbrot L, 290
Manfredi R, 319
Mani GS, 394
Manson K, 99
Manyenga D, 303
Marchisio P, 158
Markson LE, 259
Marmor M, 514
Marquina SA, 527
Massad E, 84
Massawe A, 421
Massetti A, 112
Mastroianni A, 319
Matijas L, 193
Matsuzaki H, 182
Mayer KH, 406
Mazzotta F, 462
McKee LJ, 259
McKinley GF, 147
McLane MF, 19
McLean BD, 153
McLinden RJ, 329, 343
Meda N, 290
Mehalko S, 56
Mesquita F, 84
Messari F, 363
Meyer L, 174
Mhalu F, 421
Migdal CS, 209
Mikovits J, 1
Milazzo F, 462
Mildvan D, 514
Miller WC, 303
Minkoff H, 489
Miro JM, 249
Mitchell T, 56
Mittler JE, 233

Miyoshi I, 182
Mlalasi J, 303
Molenberghs G, 38
Momita S, 182
Montaner JSG, 46, 153
Morandi B, 158
Morein B, 213
Morell-Ocaña M, 107
Moroni M, 268, 462
Morris CB, 128
Morris GF, 128
Mosca JD, 329, 343
Moss RB, 358
Motte K, 413
Msellati P, 290
Msemo G, 421
Muneyyirci-Delale O, 489
Mupanduki I, 69
Murphy EL, 193
Murphy R, 358
Murray J, 282
Musicco M, 268

Natpratan C, 495
Navia BA, 19
Nebuloni M, 139
Nelson KE, 495
Nevin T, 147
Niero F, 268
Niraroot V, 495
Nishimura H, 182
Norley S, 442
North TW, 26
Novoa P, 526
Nyambi PN, 187

O'Brien MU, 282
O'Brien TR, 427
Olivo N, 96, 431
Olofsson S, 213
Omar RF, 451
Onorato J, 158
Ortona L, 462
Östborn A, 421
Ouellet L, 282
Owens S, 147

Pahissa A, 93
Palapunya P, 495
Pampuro SE, 525, 527
Pardee AB, 120
Park I-W, 321
Park J, 321
Pastore G, 462
Pauza CD, 99
Pavan A, 112
Payne LG, 99
Pedersen BK, 433
Peeters M, 187
Peña J, 107
Peralta LM, 525
Perez-Bianco R, 428
Persin C, 442
Persoz A, 174
Peterman TA, 69
Peterson E, 358
Phair J, 363
Picchia GR, 428
Pigrau C, 93
Podzamczer D, 249
Pottage JC, 363
Powderly WG, 38, 94
Principi N, 158

Quattrone G, 75

Rabinovich RD, 527
Rabkin CS, 519
Raboud JM, 46, 153
Racca S, 139
Radice D, 268
Ravà L, 63
Ravn P, 433
Read SE, 400
Redfield RR, 329, 343
Rehle T, 500
Remington KM, 26
Reyes-Engel A, 107
Rice AP, 128
Ridolfo AL, 268
Riva A, 268
Roberts B, 99
Roberts C, 193
Robertson P, 6
Robson BA, 298
Rodriguez D, 379
Rosandich ME, 363
Rosling H, 317
Rossi L, 164
Rouamba O, 290
Rudolph D, 96, 193, 431
Ruedy J, 153
Ruiz MA, 84
Ruscetti F, 1
Rusconi S, 268

Saballs P, 249
Safrin S, 147, 358
Sakahara N, 427
Sala E, 139
Salvato MS, 99
Sandy CJ, 209
Sansolini T, 112
Santamaria JM, 249
Sauerwein HP, 482
Savignano R, 428
Scalise G, 462
Schechter MT, 46, 153
Schiavano GF, 164
Schooley RT, 363
Schreiber GB, 193
Seage GR, 406
Shafran SD, 477
Shao J, 303
Sheffet A, 75
Shepp DH, 358
Shi M, 309
Shore RE, 514
Siegal FP, 358
Silverman NS, 259
Simison D, 413
Sin DD, 477
Singer J, 46, 153
Sinicco A, 462
Siraprapasiri T, 500
Sjölander S, 213
Skurnick JH, 75
Snijders F, 276
Sodroski J, 99, 321
Sorice M, 112
Spiegelman D, 500
Srikantan V, 221
Stegagno M, 63
Steigbigel RT, 147
Stein DS, 363
Stoddart RW, 394
Swai N, 303
Switzer WM, 193

Taguchi H, 182
Tai T, 112
Takahashi H, 182
Takatsuki K, 182
Tamura K, 182
Tang H, 309
Taylor JMG, 309
Tedla N, 523
ten Berge IJM, 276
ten Kate FJW, 276
Thammapornpilap P, 500
Thielman NM, 303
Thomis J, 249
Thomson R, 193
Thorne A, 46
Thorstensson R, 317
Tierce JC, 413
Ting D, 303
Titus S, 514
Tius MA, 120
Todd KA, 69
Tomino C, 462
Tomonaga M, 182
Touzjian N, 99
Townsend L, 352
Trabattoni GR, 139
Tremblay M, 451
Trickett A, 523
Trujillo JR, 19
Tsuda H, 182
Turner BM, 259
Turner JL, 358
Tylleskär T, 317

Ugen KE, 221
Ungchusak K, 500
Uozumi K, 182

Urassa E, 421

Vago L, 139
Vahey MT, 343
Vallejo A, 529
Vallely PJ, 394
Van de Perre P, 290
van der Groen G, 187
van Rensburg EJ, 298
Vandamme A-M, 208
Vaz RS, 526
Vella S, 462
Verdejo J, 249
Ville Y, 187
Visosky AA, 352
Vogel T, 442
Vogler M, 514
Voltolin L, 268

Waldron S, 209
Wallace MR, 358
Wang Z, 128
Ward D, 413
Ward JW, 293
Waters D, 1
Watson HG, 6
Weber JT, 96, 431
Weimer LE, 462
Weiner DB, 221
Weinstein RA, 379
Weiser B, 352
Wetherill PE, 33
Wettlaufer B, 147
Wever PC, 276
Weverling GJ, 482
Wiebel WW, 282
Williams PL, 38
Williams WV, 221
Wold C, 406
Worth J, 19
Wright D, 193
Wyand M, 99

Xiong W, 128

Yamada O, 182
Yamashita M, 428
Young J, 56

Zhang Y, 202
Zhuo J, 120

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
12:535–541 © 1996 Lippincott–Raven Publishers, Philadelphia

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology Volume 12, 1996

Subject Index

Acemannan, double-blind placebo-controlled pilot trial, 153
Acute retroviral syndrome, weight loss and, 514
Acyclovir, mucocutaneous herpes simplex resistant to, 147
Adult T-cell leukemia/lymphoma
  and HTLV-I infection, 519
  intensive chemotherapy with G-CSF, 182
Africa
  delayed-type hypersensitivity testing in, 303
  early diagnosis and prediction of mother-infant transmission of HIV-1 infection in, 421
  interventions to reduce mother-child HIV-1 transmission in, 290
  konzo and HTLV-I, HIV, and HIV *gag*-encoded protein antibodies in, 317
  mother-child HTLV transmission in, 187
  proviral HTLV in, 208
  sequence variation and subtyping of HTLV/STLV-I strains in, 298
AIDS. *See also* HIV infection
  as accelerator of immune repertoire senescence, 233
  acyclovir-resistant mucocutaneous herpes simplex with, 147
  Campylobacter bacteremia in, 93
  Chinese herbal treatment for HIV-associated symptoms of, 386
  cost of lifetime health care for, 371
  costs of based on treatment protocols, 413
  didanosine *vs.* zidovudine treatment of, 462
  hospitalized tuberculosis patients and, 508
  IL-6 and b-FGF overproduction and, 95
  interest in vaccine for among gay/bisexual men, 406
  JCV-DNA and BKV-DNA in, 139
  predicting residual time to diagnosis of, 309
  prevention and control of, 69
  severe thrombocytopenia and progression to, 268
  tuberculosis and, 293
AIDS dementia complex, anti-HIV-1 envelope antibodies levels in, 19
AIDS-related cytomegalovirus retinitis, long survival in, 209
Alternative medicine, for HIV-associated symptoms, 386
Amniotic fluid analysis, for HTLV-I/II transmission, 187
Antifungal agents, for HIV-associated oral candidiasis, 470
Antiganglioside antibodies, overexpression of on lymphocyte plasma membrane, 112
Antigenemia, cytomegalovirus, 33
Anti-HIV-1 antibodies
  high levels in CSF, 19
  temporal and geographical trends in newborn screening for, 63
Antiretroviral therapy, missing data due to dropouts from randomized trials, 46
Antisense Rev response elements, 343
Antiviral drugs
  feline immunodeficiency virus mutation enhanced by, 26
  off-label use of, 56
  resistance to, 6
Antiviral evaluation, of ribavirin, 451
Apoptosis, HIV-1 effect on, 321
Argentina, reactivity of serum samples against synthetic V3-based HIV-1 peptides, 527
Auxiliary events, improving analysis of HIV survival, 174
AZT
  feline immunodeficiency virus mutation enhanced by, 26
  inhibition of murine AIDS by, 164
  resistance to, 6

B lymphocytes, immunosuppressive peptide inhibition of, 442
Bacteremia, *Campylobacter*, 93
Bahamas, HIV-infected pregnant women in, 400
Barbados, HTLV-I infection in, 519
Basic fibroblast growth factor (b-FGF), overproductions and AIDS-associated Kaposi's sarcoma, 95
Bcl-2, and programmed cell death, 321
Biological markers, as AIDS predictors, 309. *See also* Markers
Birth outcomes, of HIV-infected women, 259
BK virus-DNA, in CNS tissue and CSF of AIDS patients, 139
Brazil
  HIV in drug injectors of, 84
  HTLV-I/II survey on hemodialysis patients in, 525
Buenos Aires, HTLV-I/II survey on hemodialysis patients in, 525

Campylobacter bacteremia, in AIDS patients, 93

Candidiasis, prophylaxis for, 470
Canventol, inhibition of HIV-1 replication by, 120
$CD4^+$ count
  15 years after HIV seroconversion, 394
  costs of HIV/AIDS and, 413
  randomized trial dropouts and, 46
CD4 lymphocytes
  in HIV survival analysis, 174
  M. avium and purified protein derivative-specific cytotoxicity, 433
  percentages in HIV-infected patients, 358
  in predicting disease progression, 309
Cell harvesting, from patients with asymptomatic HIV infection, 523
Central nervous system, JCV-DNA and BKV-DNA in, 139
Cerebrospinal fluid
  high anti-HIV-1 envelope antibodies levels in, 19
  JCV-DNA and BKV-DNA in, 139
Chemotherapy, G-CSF in, 182
Childbearing women, HIV-1 prevalence in, 63
Children, aerosolized pentamidine as prophylaxis against PCP in, 158
Chinese medicine, randomized controlled trial for HIV symptoms, 386
CHOP therapy, for ATLL, 182
Chronic infection, of HTLV-I infection in Barbados, 519
Clinical trials
  for interventions to reduce mother-child transmissions, 290
  of preventive HIV vaccines, 406
Cloning, of HIV-1 genomes, 352
Cocaine
  crack, HIV risk during pregnancy and, 400
  HIV transmission and, 84
Combination therapy
  inhibition of murine AIDS by, 164
  phase 1 study of, 363
Community standard of practice, off-label drug use and, 56
Contraceptives, injectable, HIV infection and, 500
Cost analysis, of lifetime HIV-related health care costs, 371
Costs
  of HIV^+/AIDS at $CD4^+$ counts disease stages, 413
  of lifetime HIV-related health care, 371
Cytomegalovirus antigenemia test, in HIV evaluation, 33
Cytomegalovirus infection
  in HIV patient, 33
  patterns in HIV patients, 38
Cytomegalovirus retinitis, AIDS-related, long survival in, 209
Cytotoxic T lymphocytes, *Mycobacterium avium*-specific, 433

Dapsone, methemoglobinemia induced by, 477
Delayed-type hypersensitivity testing, for HIV infection in Tanzania, 303
Dermatitis, HTLV-I infection and, 519
Diagnosis, of HIV-1 in infants, 421
Diarrhea, granzyme B-expressing cytotoxic T lymphocytes and, 276
Didanosine
  for advanced HIV disease, 153
  randomized trial of, 462
  switching to, 249, 462
Dideoxycytidine 5'-triphosphate, inhibition of murine AIDS by, 164
Disease progression
  15 years after seroconversion, 394
  costs of, 413
  hyperuricemia and, 318
  marker values in predicting, 309
  with severe thrombocytopenia, 268
Drug compendia, on off-label drug use, 56
Drug injectors, HIV transmission among, 84
Drug users. *See* Injection drug users
Dual infection, HIV-1 transcriptional effects on, 342

Efe pygmies, proviral HTLV in, 208
Envelope epitope, conserved, 221
Epidemiology, of HIV seroconversion among injection drug users, 514
Etoposide, for ATLL, 182

Familial clustering, of HTLV-I/II, 187
Feline immunodeficiency virus, mutation frequency enhanced by AZT, 26
Follow-up study, of HTLV-I infection in Barbados, 519
France, auxiliary events in survival analysis of HIV-infected patients in, 174
Free solution capillary electrophoresis (FSCE), in quantifying HIV-1 RNA, 107

Gabon, mother-child transmission of HTLV in, 187
Gag-encoded proteins, konzo and, 317
Gay/bisexual men, interest in HIV vaccine clinical trials among, 406
Glycans, N-linked, in V4-V5 region of HIV-1 glycoprotein gp160, 213
GM3, overexpression on lymphocyte plasma membrane, 112
gp160, N-linked glycans in V4-V5 region of, 213
gp41 monoclonal antibody, 221
Granulocyte colony-stimulating factor (G-CSF) support, for ATLL, 182
Granzyme-B-expressing cytotoxic T-lymphocytes, increased, 276

Health care, lifetime cost of, 371
Hematotoxicity, of ribavirin, 451
Hemodialysis patients, HTLV-I/II survey on, 525
Hemophilia, 15 years after HIV seroconversion, 394
Hepatitis, transmission among drug injectors, 84
Herbal treatment, randomized controlled trial for HIV symptoms, 386

Herpes simplex, acyclovir-resistant mucocutaneous with AIDS, 147
Heterosexual transmission, HIV-1 RNA plasma levels and, 427
Heterosexuals, micronutrient profiles in HIV-1-infected, 75
HIV-1 antibodies
gp 120, in AIDS dementia complex, 19
gp41 monoclonal, 221
konzo and, 317
screening for in newborns, 63
HIV-1 gp160, N-linked glycans in V4-V5 region of, 213
HIV infection. *See also* AIDS; HIV-1 infection
acemannan for, 153
acyclovir-resistant mucocutaneous herpes simplex with, 147
aerosolized pentamidine for PCP in children with, 158
auxiliary events improving analysis of survival in, 174
Chinese herbal treatment for symptoms associated with, 386
costs based on treatment protocols, 413
cytomegalovirus infection in, 33
dapsone- and primaquine-induced methemoglobinemia in, 477
delayed-type hypersensitivity testing for in Tanzania, 303
determinants in female sex workers in Thailand, 500
dropouts from randomized trials in, 46
early clinical markers and CD4 percentage in, 358
granzyme B in intestine with, 276
hyperuricemia and progression of, 318
interest in vaccine among gay/bisexual men, 406
JCV-DNA and BKV-DNA in CNS and CSF with, 139
lifetime cost of health care for, 371
menstrual function in, 489
off-label drug use in, 56
opportunistic infection patterns in, 38
overexpression of monosialoganglioside GM3 on lymphocyte plasma membrane in, 112
Pneumocystis carinii pneumonia with, 379
predicting residual time to AIDS diagnosis, 309
in pregnant women in Bahamas, 400
prenatal care and birth outcomes in women with, 259
prophylaxis for oral candidiasis with, 470
public funded counseling and testing for, 69
risk behaviors among injection drug users, 202
switching form zidovudine to didanosine for, 249
targeting population for testing, 69
transcriptional effects on superinfection in, 342
transmission patterns in drug injectors, 84
tuberculosis patients and epidemic of, 508
weight loss and, 514
HIV-1 infection
combination therapy for, 363
effects on programmed cell death, 321
immunosuppressive peptide of, 442
inhibition of replication by Canventol, 120
interventions to reduce mother-child transmissions of, 290
measuring incidence in northern Thailand, 495
micronutrient profiles in heterosexual adults, 75
molecular cloning of genomes, 352
p24 antigen assay in early diagnosis and prediction of, 421
predictive value for survival of soluble tumor necrosis factor receptors for, 482
severe thrombocytopenia with, 268
Tat protein binding to human TAT-binding protein, 128
15-year post-seroconversion cohort study of, 394
zidovudine resistance-associated genotypes in, 6
HIV replication inhibition, by sense and antisense Rev response elements, 343
HIV-1 RNA
direct quantification of in human plasma, 107
plasma levels and heterosexual transmission from transfusion recipients, 427
HIV-1 vaccine, SHIV for testing, 99
Homeostasis, T-cell, 233
Homosexuality, preventive HIV vaccines and, 406
Honduras, HTLV-I/II infections in, 529
Hospital characteristics, resource utilization for patient with PCP and, 379
Household contact, HTLV-I transmission by, 519
HTLV-I antibodies, konzo and, 317
Human immunodeficiency virus. *See* HIV infection; HIV-1 infection
Human monoclonal antibody, HIV-1 gp41, 221
Human T-cell lymphotropic/leukemia virus (HTLV) antibody enzyme immunoassay, specificity of, 526
Human T-cell lymphotropic/leukemia virus (HTLV) infection, transmission among drug injectors, 84
Human T-cell lymphotropic/leukemia virus I (HTLV-I) infection
in Barbados, 519
molecular genetics of, 1
sequence variation and subtyping of, 298
Human T-cell lymphotropic/leukemia virus I/II (HTLV-I/II) infection
in Honduras, 529
indeterminate serology and natural killer cell expansion, 428
male-to-female transmission of, 193
mother-to-child transmission of, 187
prevalence and risk factors for among hospitalized patients in South Bronx, 96, 431
proviral, in Efe pygmies, 208
survey on hemodialysis patients, 525
Humoral response, virus-neutralizing, 213
Hyperuricemia, HIV progression and, 318

Immune response, HIV-accelerated senescence of repertoire, 233
Immunity, micronutrients and, 75
Immunization, tuberculosis, 433
Immunoassay, HTLV antibody enzyme, 526
Immunocompromise, cytomegalovirus infection and, 33
Immunogen, in humoral response, 213
Immunosuppression, HIV-1 immunosuppressive peptide in, 442
Immunotherapy
active, 221

adoptive, harvesting cells for, 523
HIV-1 passive, 221
In situ hybridization, JCV-DNA and BKV-DNA evaluation by, 139
Incidence, among female sex workers in Thailand, 495, 500
Infants
aerosolized pentamidine as prophylaxis against PCP in, 158
early diagnosis of HIV-1 infection in, 421
of HIV-infected mother, 259
Infectious disease, transmission among drug injectors, 84
Infectious molecular clones, HTLV-1 provirus, 1
Injection drug users
HIV risk behaviors among, 202
risk behavior and HIV seroincidence among, 282
weight loss with HIV seroconversion among, 514
Insurance reimbursement, off-label drug use and, 56
Interferon-α, predictors for survival during treatment with, 482
Interleukin-6, overproductions and AIDS-associated Kaposi's sarcoma, 95
Interventions, to reduce mother-child transmissions, 290
Italy, HIV-1 antibodies screening in newborns in, 63

JC virus-DNA, in CNS tissue and CSF of AIDS patients, 139
Jurkat cell, HIV-1 infection and, 321

Kaposi's sarcoma, IL-6 and b-FGF overproduction preceding, 95
Karnofsky score, in HIV survival analysis, 174
Konzo, antibodies and, 317

L-697,661, phase 1 study of combination therapy with, 363
Lentivirus mutation frequency, AZT and, 26
Letters to Editor
Campylobacter spp. bacteremia in AIDS patients, 93
Campylobacter spp. bacteremia in AIDS patients (authors' reply), 94
Correlation of HIV-1 RNA levels in plasma and heterosexual transmission of HIV-1 from infected transfusion recipients, 427
HTLV-I/II indeterminate serology and natural killer cell expansion, 428
HTLV-I/II survey on hemodialysis patients in Buenos Aires, 525
Hyperuricemia and progression of HIV disease, 318
IL-6 and b-FGF overproductions precede development of AIDS-associated Kaposi's sarcoma, 95
Konzo, an epidemic spastic paraparesis in Africa, is not associated with antibodies to HTLV-I, HIV, or HIV *gag* proteins, 317
Long survival in AIDS-related cytomegalovirus retinitis, 209
Presence of human T-cell lymphotropic virus types I and II infections in Honduras, 529
Prevalence of and risk factors for HTLV-I and HTLV-II infection among patients at a hospital in the South Bronx, New York, 96, 431
Proviral HTLV-I and HTLV-II in the Efe pygmies of northeastern Zaire, 208
Reactivity of Argentine serum samples against synthetic V3-based HIV-1 peptides, 527
Safety and feasibility of harvesting cells for adoptive immunotherapy from patients with asymptomatic HIV infection, 523
Specificity of HTLV antibody enzyme immunoassay, 526
Viral bacterial vaccination rates in HIV-infected patients, 528
Leukoencephalopathy, progressive multifocal, 139
Lifetime health care cost, HIV-related, 371
Lymphocyte counts, in HIV infection testing, 303
Lymphocyte plasma membrane, overexpression of monosialoganglioside GM3 on, 112

Macaques, SHIV for testing HIV-1 vaccine in, 99
Male-to-female transmission, of HTLV-I/II, 193
Markers
early clinical, 358
in HIV survival analysis, 174
predicting mother-infant transmission, 421
predicting survival in symptomatic HIV-1 infection, 482
surrogate, 153, 358
values in predicting residual time to AIDS diagnosis, 309
Menstrual function, in HIV-infected women with AIDS, 489
Menstruation disorders, in HIV-infected women, 489
Methemoglobinemia, dapsone- and primaquine-induced, 477
Microglobulin, in predicting residual time to AIDS diagnosis, 309
Micronutrient profiles, in HIV-1-infected heterosexual adults, 75
Mitoxantrone, for ATLL, 182
Molecular cloning, of full-length HIV-1 genomes, 352
Molecular genetics, of HTLV-1, 1
Molecular subtypes, HTLV-I, STLV-I, and PTLV-I, 298
Monoclonal antibody, to HIV-1 gp41, 221
Monosialoganglioside GM3, overexpression on lymphocyte plasma membrane, 112
Mother-infant transmission
of HTLV-I/II, 187
interventions to reduce, 290
p24 antigen assay in prediction of, 421
Multicenter AIDS cohort, auxiliary events improving analysis of survival in, 174
Murine AIDS
antiviral efficacy and toxicity of ribavirin in, 451
inhibition of, 164
Mutations
frequencies in FIV, 26

of HIV-1 genomes, 6
Mycobacterium avium complex
cytotoxicity mediated by $CD4^+$ lymphocytes, 433
patterns in HIV patients, 38
Mycosis, systemic patterns in HIV patients, 38

Natural killer cell expansion, HTLV-I/II indeterminate serology and, 428
Necrosis factor-[κ]B activation, 120
Neopterin, in predicting residual time to AIDS diagnosis, 309
New York City, hospitalized tuberculosis patients in, 508
Newborns, anti-HIV-1 antibodies screening among, 63
Nucleotide sequence, HIV-1 genome, 6
Nystatin pastilles, prophylactic for HIV-associated oral candidiasis, 470

Off-label drug use, in HIV disease, 56
Oligosaccharide, in humoral response, 213
Opportunistic infections. *See also specific infections*
cytotoxic T lymphocytes and, 433
patterns in HIV patients, 38
Oral candidiasis, prophylaxis for, 470

p24 antigen
in early diagnosis and prediction of mother-infant transmission, 421
in measuring HIV-1 incidence, 495
Patient characteristics, resource utilization for PCP and, 379
Pentamidine, long-term aerosolized as prophylactic, 158
Peptides
HIV-1 immunosuppressive, 442
V3-based HIV-1, reactivity of serum samples against, 527
Pharmacokinetics
of acemannan, 153
of zidovudine and L-697,661, 363
Phase 1 study, of zidovudine/L-697,661 combination therapy, 363
Phylogenetic analysis, of HIV-1 genomes, 6
Plasma membrane, overexpression of monosialoganglioside GM3 on, 112
Plasma viral RNA, molecular cloning of HIV-1 genomes from, 352
Pneumocystis carinii pneumonia
aerosolized pentamidine as prophylaxis against, 158
patterns in HIV patients, 38
predictors of resource utilization for hospitalized patients with, 379
Polymerase chain reaction
for HTLV-I/II, 187
JCV-DNA and BKV-DNA evaluation by, 139
Predictive markers
of mother-infant transmission, 421
for survival in symptomatic HIV-1 infection, 482
Pregnancy
HIV infection during, 400
outcome with prenatal care of HIV-infected women, 259
Prenatal care, of HIV-infected women, 259
Prevention
with HIV counseling and testing, 69
of HIV in injection drug users, 282
HIV vaccines in, 406
Primaquine, methemoglobinemia induced by, 477
Primate T-cell lymphotropic virus type I (PTLV-I), sequence variation and subtyping of, 298
Programmed cell death, HIV-1 effect on, 321
Progressive multifocal leukoencephalopathy, JCV-DNA and BKV-DNA in, 139
Prophylactic therapy
long-term aerosolized pentamidine in, 158
with nystatin pastilles for candidiasis, 470
for opportunistic infection in HIV patients, 38
Proportional hazards model, for opportunistic infection in HIV patients, 38
Provirus clones, HTLV-1, 1
Pulmonary tuberculosis, HIV epidemic and, 508
Purified protein derivative-specific cytotoxicity, 433

Quality of care, for *Pneumocystis carinii* pneumonia patients, 379
Quality of life, Chinese herbal treatment and, 386

Randomized trials, missing data due to dropouts from, 46
Ranimustine, for ATLL, 182
Residual time, marker values in predicting, 309
Resistance
to acyclovir, 147
to zidovudine in HIV-1, 6
Resource utilization predictors, for PCP-hospitalized patients, 379
Retinitis, AIDS-related cytomegalovirus, 209
Retroviral infection
molecular genetics of, 1
murine, 164
sense and antisense Rev response elements in HIV-based vectors of, 343
weight loss and, 514
Rev response elements, in HIV-based retroviral vectors, 343
Rhesus monkeys, SHIV for testing HIV-1 vaccine in, 99
Ribavirin, antiviral efficacy and toxicity of in MAIDS, 451
Risk behavior
among injection drug users, 202
HIV seroincidence among out-of-treatment injection drug users and, 282
Risk factors
among female sex workers in Thailand, 500
among hospitalized patients, 431
auxiliary events improving detection of, 174
for HTLV-I/II infection, 96, 431
for pregnant women, 400

Screening, for anti-HIV-1 antibodies among newborns, 63
Senescence, HIV-accelerated, 233
Sense Rev response elements, 343
Sequence analysis: HTLV-I, STLV-I, and PTLV-I, 298
Seroconversion rates, among female sex workers in Thailand, 500
Serum, anti-HIV-1 envelope antibodies levels in, 19
Sex workers
  HIV-1 incidence in, 495
  HIV infection determinants in, 500
Sexual transmission
  HIV-1 RNA plasma levels and, 427
  of HTLV-I/II, 193
Simian T-cell lymphotropic virus type I, sequence variation and subtyping of, 298
Simian/human immunodeficiency virus (SHIV), in testing HIV-1 vaccine candidates, 99
Small intestine, granzyme B-expressing cytotoxic T lymphocytes in, 276
South Africa, sequence variation and subtyping of HTLV/STLV-I strains in, 298
South Bronx, HTLV risk factors and prevalence in, 96, 431
Substance abuse, pregnancy outcome and in HIV-infected mother, 259
Subtyping, of HTLV-I, STLV-I, and PTLV-I, 298
Superinfection, transcriptional effects of in HIV, 342
Surrogate markers
  of acemannan, 153
  in HIV-infected patients, 358
Surveillance, of AIDS patients in U.S., 293
Survival
  in AIDS-related cytomegalovirus retinitis, 209
  auxiliary events improving analysis of, 174
  didanosine *vs.* zidovudine in, 462
  in hospitalized tuberculosis patients, 508
  soluble TNF receptors in predicting, 482
Symptomatic disease progression, switching from zidovudine to didanosine for, 249
Syphilis, transmission among drug injectors, 84

T lymphocytes
  granzyme B-expressing cytotoxic, 276
  homeostasis, competition, and drift of, 233
  immunosuppressive peptide inhibition of, 442
  transient infections of, 1
Tanzania
  delayed-type hypersensitivity testing in, 303
  early diagnosis and prediction of mother-infant transmission of HIV-1 infection in, 421
Target population, for HIV counseling and testing, 69
Tat protein
  binding human TATA-binding protein, 128
  in HIV-based retroviral vectors, 343
TATA-binding protein, HIV-1 Tat protein binding, 128
Tat-induced tar-independent mechanism, inhibition of HIV-1 replication by, 120
T-cell-mediated cytotoxicity, *Mycobacterium avium* specific, 433
Thailand
  HIV infection determinants in female sex workers of, 500
  measuring HIV-1 incidence in, 495
Thrombocytopenia, HIV-1-related, 268
Trace metals, in HIV-1-infected heterosexual adults, 75
Transactivation response element, in HIV-based retroviral vectors, 343
Transactivation-defective mutants, HIV-1 Tat protein, 128
Transcription
  HIV-1, 120
  HIV-1 Tat protein, 128
  superinfection and, 342
Transfusion recipients, heterosexual transmission of HIV-1 by, 427
Transmembrane glycoprotein, in T and B cell suppression, 442
Transmission
  among drug injectors, 84
  by female sex workers, 500
  heterosexual, 427
  male-to-female, 193
  mother-child, 187, 290, 421
  prediction of, 421
Treatment protocols, costs of HIV/AIDS based on, 413
Trial dropouts, missing data due to, 46
Trifluridine, pilot study for herpes simplex treatment, 147
Tuberculosis
  in AIDS patients, 293
  cytotoxic T lymphocytes and, 433
  HIV epidemic effect on hospitalized patients with, 508
Tumor necrosis factor-α, inhibition by Canventol, 120
Tumor necrosis factor receptors, soluble, in predicting survival with symptomatic HIV-1 infection, 482

United States, tuberculosis among AIDS patients in, 293

Vaccination rates, in HIV-infected patients, 528
Vaccines
  HIV-1, testing of, 99
  interest in among gay/bisexual men, 406
V3-based HIV-1 peptides, reactivity of serum samples against, 527
Vindesine, for ATLL, 182
Viral bacterial vaccination, in HIV-infected patients, 528
Viral glycoproteins, N-linked glycans of, 213
Viral load, in HTLV-I/II transmission, 193
Viremia, cytomegalovirus, 33

Weight loss, with HIV seroconversion in injection drug users, 514

West Africa, interventions to reduce mother-child HIV-1 transmission in, 290
Western blot, for HTLV-I/II, 187
Wild-type mutants, of HIV-1 Tat protein, 128
Women. *See also* Mother-infant transmission; Sex workers
  menstrual function with HIV infection, 489
  prenatal care and birth outcomes of HIV-infected, 259
Zaire, proviral HTLV in, 208
Zidovudine
  for advanced HIV disease, 153
  continuation of *vs.* switching to didanosine, 462
  phase 1 study of combination therapy with, 363
  predictors for survival during treatment with, 482
  resistance to, evolution of, 6
  switching from, 249